Multiple Sclerosis Trial, Not Yet Recruiting NCT06171334 Sponsor: University of Calgary Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Not Yet Recruiting

NCT06171334
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • A person who has given written consent to participate in the trial.
  • Men and women aged between 18 and 65 years (inclusive).
  • People who have been diagnosed with Primary Progressive Multiple Sclerosis, based on current diagnostic standards.
  • People whose level of disability, as measured by a standard MS scale called the Expanded Disability Status Scale (EDSS), falls between 4.0 and 6.5 at the screening stage.
  • People who take 5.5 seconds or more to walk 25 feet (about 7.6 metres) during their screening assessment (based on the average of two attempts).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose MRI scan at screening shows active areas of inflammation in the brain or spine (called gadolinium enhancing lesions).
  • People with a known history of kidney problems (renal insufficiency).
  • People with a known history of significant liver problems.
  • People with a known allergy to the contrast dye (gadolinium) used in some MRI scans.
  • People currently taking immune-modulating medications such as ocrelizumab or hydroxychloroquine.
  • People currently taking blood-thinning medications (such as warfarin, apixaban, rivaroxaban, dabigatran, or enoxaparin).
  • People currently taking Fampridine or 4-aminopyridine.
  • People who plan to start taking Fampridine or 4-aminopyridine at any point during the study.
  • People who plan to start taking Baclofen or Tizanidine during the study period.
  • People who increase their dose of Baclofen or Tizanidine at any point during the study.
  • People who receive Botulinum toxin (such as Botox) injections into the leg muscles during the study period.
  • People who are unable or unwilling to have gadolinium-enhanced MRI scans.
  • People with a known history of blood clots in the arms or upper limbs.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
University of Calgary
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 March 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Timed 25-foot walk

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov